Top

Reactions Weekly

Published in:

01-11-2022 | Breast Cancer | Case report

Exemestane/letrozole/ribociclib

Hepatic toxicity, haematological toxicity and lack of efficacy: 2 case reports

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Staropoli N, et al. Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program. Current Oncology 29: 6635-6641, No. 9, 2022. Available from: URL: http://doi.org/10.3390/curroncol29090521

Title: Exemestane/letrozole/ribociclib
Hepatic toxicity, haematological toxicity and lack of efficacy: 2 case reports
Publication date: 01-11-2022
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Exemestane
Letrozole
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-28158-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Exemestane/letrozole/ribociclib

Hepatic toxicity, haematological toxicity and lack of efficacy: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Antineoplastics

Clopidogrel/ticagrelor

Ad26.cov2-s/elasomeran/tozinameran

Bupivacaine/fentanyl

Aspirin/clopidogrel

Pembrolizumab